SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Siegel, Corey A.; Melmed, Gil Y.; McGovern, Dermot P.; Rai, Victoria; Krammer, Florian; Rubin, David T.; Abreu, María T.; Dubinsky, Marla

doi:10.1136/gutjnl-2020-324000

Cited by 178 publications

(215 citation statements)

References 36 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…We did not sample patients after a single dose. Our observations strongly support the recent vaccination endorsement by the International Organization for the Study of IBD (18) and lessen theoretical concerns about diminished response to immunization for influenza (19,20)…”

Section: Discussionsupporting

confidence: 83%

Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease

Dailey

Kozhaya

Dogan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Characterization of neutralization antibodies to SARS-CoV-2 infection or vaccination in children and young adults with inflammatory bowel disease (IBD) receiving biologic therapies is crucial. Methods: We performed a prospective longitudinal cohort study evaluating SARS-CoV-2 Spike protein receptor binding domain (S-RBD) IgG positivity along with consistent clinical symptoms in patients with IBD receiving infliximab or vedolizumab. Serum was also obtained following immunization with approved vaccines. IgG antibody to the spike protein binding domain of SARS-CoV-2 was assayed with a fluorescent bead-based immunoassay that takes advantage of the high dynamic range of fluorescent molecules using flow cytometry. A sensitive and high-throughput neutralization assay that incorporates SARS-CoV-2 Spike protein onto a lentivirus and measures pseudoviral entry into ACE2 expressing HEK-293 cells was used. Results: 436 patients were enrolled (mean age 17 years, range 2-26 years, 58% male, 71% Crohn disease, 29% ulcerative colitis, IBD-unspecified). 44 (10%) of enrolled subjects had SARS-CoV-2 S-RBD IgG antibodies. Compared to non-IBD adults (ambulatory) and hospitalized pediatric patients with PCR documented SARS-CoV-2 infection, S-RBD IgG antibody levels were significantly lower in the IBD cohort and by 6 months post infection most patients lacked neutralizing antibody. Following vaccination (n=33) patients had a 15-fold higher S-RBD antibody response in comparison to natural infection, and all developed neutralizing antibodies to both wild type and variant SARS-CoV-2. Conclusions and Relevance: The lower and less durable SARS-CoV-2 S-RBD IgG response to natural infection in IBD patients receiving biologics puts them at risk of reinfection. The robust response to immunization is likely protective.

show abstract

Section: Discussionsupporting

confidence: 83%

Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease

Dailey

Kozhaya

Dogan

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The British Society of Gastroenterology provided recommendations for the SARS-CoV-2 vaccination in IBD patients [ 6 ]. The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) recommends that patients with IBD should be vaccinated against SARS-CoV-2, and vaccination should not be deferred because a patient with IBD is receiving immune-modifying therapies [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey

2021

View full text Add to dashboard Cite

Background Vaccination against COVID-19 is a major public health challenge, including the community of patients with inflammatory bowel disease. Vaccination coverage is suboptimal in inflammatory bowel disease population. It is of paramount importance to ensure an effective and rapid vaccination program with the adherence of the largest number of well-informed patients. Aims We assessed the acceptance of COVID-19 vaccination among inflammatory bowel disease patients. Methods We performed a survey as part of routine practice, between January 8th and February 22nd, 2021. All consecutive adult patients followed at Nancy University Hospital for inflammatory bowel disease were included. Patients completed a self-administered, structured, paper-based questionnaire. Demographic data, medical history, knowledge, and perceptions of COVID-19 vaccination were collected. Results Among the 104 patients who responded to the survey, 57 patients (54.8%) had intent to receive the COVID-19 vaccine. Vaccine efficacy, social responsibility, herd immunity, and desire to return to normal life were associated with self-reported willingness to receive a vaccine (20.2%, 20.2%, 11.5%, and 15.4%, respectively). Unknown long-term safety, risk of adverse reaction to vaccine and concern that the vaccine is being developed too quickly were the most commonly reported reasons for non-uptake (27.9%, 15.4%, and 12.5%, respectively). Conclusion Half of the patients with inflammatory bowel disease would like to be vaccinated against SARS-CoV-2. This rate is similar to that reported in the French general population. Despite some concerns, patients with inflammatory bowel disease understood the necessity to be vaccinated against COVID-19.

show abstract

“…However, the rapid development of SARS-CoV-2 vaccines has led to uncertainties among the Italian population and among patients with inflammatory bowel disease (IBD), despite the international recommendations. 1 , 2 To develop strategies against vaccine hesitancy in IBD patients, we measured the acceptance of anti-SARS-CoV-2 vaccination in this population. An anonymous web-based questionnaire was sent from April 5 through April 15, 2021 to patients attending our clinic addressing sociodemographic and therapeutic features, in addition to willingness and potential concerns on anti-SARS-CoV-2 vaccination.…”

mentioning

confidence: 99%

Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey

Crispino

Brinch

Carrozza

et al. 2021

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Abstract: Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Cited by 178 publications

References 36 publications

Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease

Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey

Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey

Contact Info

Product

Resources

About